Current Psoriasis News and Events | Page 13

Current Psoriasis News and Events, Psoriasis News Articles.
Sort By: Most Relevant | Most Viewed
Page 13 of 14 | 534 Results
Government psoriasis research funding down over last decade while NIH budget up 148%
Over the last decade, as NIH funding increased by 148%, psoriasis research funding at NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) actually decreased by 13%. (2004-05-17)

FDA approves Enbrel to treat psoriasis
Amgen (N), announced on Friday, April 30 that Enbrel(etanercept) has been approved by the U.S. Food and Drug Ad ASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYEministration (FDA) for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The psoriasis indication marks the fifth disease for which ENBREL has received an FDA approval in just over five years. (2004-05-02)

Multiple factors affect psoriasis treatment compliance
Psychological, social, and disease-related issues may influence a patient's compliance with psoriasis treatment, according to an article in the April issue of The Archives of Dermatology, one of the JAMA/Archives journals. (2004-04-19)

A multi-institutional study may offer clues for the treatment of some autoimmune diseases
Preliminary data confirm the hypothesis that use of the PNP inhibitor BCX-1777 to elevate plasma dGuo results in elevation of cellular dGTP and a corresponding reduction of leukemic T-cells. An evaluation of the clinical efficacy is scheduled to be determined in several Phase II clinical trials. Additionally, these data support use of PNP inhibitors in treatment of other T-cell proliferative disorders, such as psoriasis and rhematoid arthritis. (2004-04-19)

New study finds even a 'small' amount of psoriasis can negatively impact daily life
A study released Saturday in a special issue of the Journal of Investigative Dermatology (JID) finds that many adults with relatively small areas of psoriasis on their skin nevertheless report high levels of dissatisfaction with their current treatment, and also feel that psoriasis is a problem in their daily life. (2004-03-29)

HPV in skin of psoriasis patients treated with medication and UV light therapy
Patients with psoriasis who have been treated with a combination of drug (psoralen) and ultraviolet light therapy have an increased prevalence of human papilloma virus (HPV) in their skin, according to an article in the March issue of The Archives of Dermatology, one of the JAMA/Archives journals. (2004-03-15)

Survey shows impact of psoriasis is more than skin deep
People with psoriasis experience a crisis in self-confidence so severe it can darken almost every aspect of life, from the quality of a person's love life to performance on the job and day-to-day social interactions. These are some of the dramatic insights gleaned from a new survey of people with moderate-to-severe psoriasis. Psoriasis is a chronic, life-altering disease that affects more than 4.5 million adults or 1 in 50 people in the United States. (2004-02-09)

Lunch workshop at the American Association for the Advancement of Science (AAAS) Annual Meeting
An educational lunch workshop, (2004-02-06)

A new direction for psoriasis research?
The National Psoriasis Foundation today hailed research that may eventually lead to additional therapies for treating psoriasis. A new Journal of Investigative Dermatology paper by Dr. Helen S. Young and colleagues at the University of Manchester (UK) provides the first evidence that there are alterations in a gene involving the development of the vascular system that may contribute to psoriasis susceptibility. (2004-01-03)

Medication provides effective treatment for moderate to severe psoriasis
Patients with moderate to severe psoriasis who were administered the medication efalizumab experienced significant improvements, with a reduction in the frequency and severity of symptoms, according to an article in the December 17 issue of The Journal of the American Medical Association (JAMA). (2003-12-16)

Dec. 17 JAMA study shows new 'biologic' drug reduces psoriasis symptoms, improves quality of life
Biologics are a new approach to treating psoriasis, according to JAMA lead author Dr. Kenneth Gordon, director, Loyola Psoriasis Center, Loyola University Health System. (2003-12-16)

Alefacept effective in treating patients with psoriasis
Patients with psoriasis treated with the drug alefacept experienced a reduction in severity of their skin disease, according to an article in the December issue of The Archives of Dermatology, one of the JAMA/Archives journals. (2003-12-15)

Glycerin may help skin disease, study finds
Glycerin, commonly found in skin care products because it attracts water and helps skin look better, may have therapeutic value as well, according to researchers at the Medical College of Georgia. (2003-12-02)

Psoriasis may increase risk for certain cancers
Patients with the skin disease psoriasis may be at an increased risk for developing lymphoma, according to an article in the November issue of The Archives of Dermatology, one of the JAMA/Archives journals. (2003-11-17)

Three genes linked to psoriasis susceptibility identified on chromosome 17
Researchers using data gleaned from a tissue bank created by the National Psoriasis Foundation have identified three of the first genes associated with psoriasis. The finding, published in the December 2003 issue of the prestigious journal Nature Genetics, marks a significant advance in the understanding of psoriasis, an immune-mediated disease with both genetic and environmental triggers, and may lead to new treatments for the disease. (2003-11-09)

Ten-year study leads researchers to psoriasis genes
After a decade of searching, researchers have identified three genes linked to psoriasis, a potentially debilitating and disfiguring skin condition characterized by burning or itching patches of raised red skin. (2003-11-09)

FDA approves Raptiva™ (efalizumab) for chronic moderate-to-severe plaque psoriasis
Genentech, Inc. and XOMA Ltd. announced today that Raptiva™ (efalizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic moderate-to-severe plaque psoriasis in adults age 18 or older who are candidates for systemic therapy or phototherapy. Raptiva is the first biologic therapy that is designed to provide continuous control of chronic moderate-to-severe plaque psoriasis and can be self-administered by patients as a single, once-weekly, subcutaneous injection. (2003-10-27)

A spoon full of sugar helps inflammation go down
In the October 1 issue of the JCI, Charles Dimitroff and colleagues from Harvard Medical School introduce a new strategy for the inhibition of selectin ligand production, which consequently prevents the development of allergic reactions in the skin. The agent used - a novel fluorosugar compound, 4-F-GlcNAc -- inhibited inflammatory responses in the skin with higher efficacy than glucocorticoids or calcineurin inhibitors currently available for the treatment of allergic skin reactions such as psoriasis and atopic dermatitis. (2003-10-01)

Drug developed for rare disease may help millions more as treatment for cancer, autoimmune diseases
An anti-angiogenesis drug developed at the University of Michigan is showing promise in studies of three different disease families, including multiple forms of cancer. The drug, tetrathiomolybdate or TM, essentially wages war against copper, which serves to choke off tumor growth, fibrosis and inflammation. (2003-09-10)

Psoriasis treatment based on Weizmann Institute Research passes phase II clinical trials
Psoriasis is a chronic skin disease with as yet no cure that affects approximately 4.5 million people in the U.S. and 5.7 million people in Europe. About 10% of these people develop chronic inflammation of the joints called psoriatic arthritis. In clinical trials testing a drug based on the discovery of Prof. David Wallach of the Weizmann Institute's Biological Chemistry Department, the condition of psoriasis and psoriatic arthritis patients was greatly improved. The treatment had no adverse effects. (2003-08-11)

ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
Amgen (NASDAQ: AMGN), the world's largest biotechnology company, and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announce that patients in a second phase 3 clinical study assessing the efficacy and tolerability of ENBREL (etanercept) in the treatment of moderate to severe plaque psoriasis experienced significant and rapid improvement in their symptoms. Psoriasis affects nearly 7 million Americans, one million of whom have moderate to severe plaque psoriasis. (2003-06-20)

New Zealand biotech: An emerging global presence
More than one dozen New Zealand companies, involved in a range of leading-edge human therapeutics and agricultural products, are participating in BIO 2003 in Washington, DC, each representing world-class biotech innovation and a powerful product pipeline. (2003-06-16)

The National Psoriasis Foundation announces new sources of help for researchers and physicians
The National Psoriasis Foundation today announced the granting of $220,000 to researchers studying the immunology and genetics of psoriasis; and the publication of Therapy of Moderate-to-Severe Psoriasis, a guide for medical professionals who treat the more than 1 million U.S. adults who have moderate-to-severe psoriasis. (2003-04-30)

Green tea linked to skin cell rejuvenation
Research into the health-promoting properties of green tea is yielding information that may lead to new treatments for skin diseases and wounds. (2003-04-24)

Results from open-label Raptiva™ study suggest continued benefit with long-term treatment
Genentech and XOMA today announced preliminary results from an open-label, multicenter trial evaluating the long-term safety and tolerability of continuous RaptivaTM (efalizumab) treatment in patients with moderate-to-severe psoriasis. The data were presented on Saturday, March 22 at the 61st annual American Academy of Dermatology meeting being held in San Francisco. (2003-03-24)

Phase III study results with Raptiva™ in the treatment of psoriasis presented at Annual AAD meeting
Genentech and XOMA announced positive results from a randomized Phase III clinical trial with RaptivaTM (efalizumab) that studied efficacy and safety in the treatment of adults with moderate-to-severe plaque psoriasis. The study results were presented during a session on emerging biologic therapies for psoriasis at the 61st annual American Academy of Dermatology meeting. (2003-03-24)

Newly approved psoriasis drug invented and tested at Univ. of Michigan
The University of Michigan Health System welcomes the approval by the U.S. Food and Drug Administration of a psoriasis treatment, alefacept or Amevive, that was first developed in a U-M laboratory. The University shares the patent on the compound with Biogen and a former U-M scientist. UMHS also played a major role in the advanced-phase clinical trials that demonstrated alefacept's ability to significantly ease or clear the painful symptoms of psoriasis. (2003-01-31)

NPF says FDA approval of new psoriasis drug signals new era of care
The National Psoriasis Foundation issued a statement today in support of the Food and Drug Administration's (FDA) approval of the first biologic drug to treat psoriasis. The FDA has approved Biogen's alefacept (brand name Amevive) to treat moderate to severe psoriasis. (2003-01-31)

Schizophrenia drugs increase risk of cardiac arrest
Patients with schizophrenia who take antipsychotic drugs are more likely to have a cardiac arrest than non-schizophrenic patients, finds a study in this week's BMJ. (2002-11-07)

Schizophrenia drugs linked to increased risk of heart attack
Patients with schizophrenia who take antipsychotic drugs are more likely to have a cardiac arrest than non-schizophrenic patients, finds a study in this week's BMJ. Using data from three US Medicaid programmes, researchers compared the frequency of cardiac events among patients with treated schizophrenia and control patients with psoriasis or glaucoma. They also compared the cardiac risk of different antipsychotic drugs (thioridazine, haloperidol, risperidone, and clozapine). (2002-11-07)

Use of vitamin A cream may prevent skin cancer
Use of topical tazarotene, a vitamin A derivative, has significant potential for the prevention of basal cell carcinoma in people predisposed to the disease, according to a study presented at the American Association for Cancer Research's (AACR) first annual Frontiers in Cancer Prevention Research meeting. The researchers found an 85 percent inhibition of both tumor number and size in the tazarotene-treated mice compared to mice administered a placebo. (2002-10-16)

Eczema patients lack natural antibiotic in skin
Patients with atopic dermatitis, or eczema, are susceptible to bacterial infections of their skin because they fail to produce two antimicrobial peptides. The findings demonstrate for the first time the clinical significance of these peptides in humans, and suggest that a medication containing or inducing the peptides may fight the infections that plague millions of atopic dermatitis patients. The accompanying editorial in the New England Journal of Medicine called it a (2002-10-09)

Promoting wound repair
Researchers at The Scripps Research Institute (TSRI) have identified a major role in promoting wound repair played by a mysterious type of immune cell that resides mainly in the skin and gut--the gamma-delta T cell. The findings, published in the current issue of the journal Science, should be important for scientists who are interested in treating diseases that arise from epithelial cell disorders, like asthma, psoriasis, cancers, and inflammatory bowel disease. (2002-04-25)

A new strategy for treating psoriasis
Dexamethasone and other steroids used for treating psoriatic skin inflammation probably act in part by inducing I-kB, thus preventing NF-kB from reaching the nucleus and trans-activating its many target genes, including those involved in T cell-dependent inflammation. Zollner and colleagues now propose a different means to this same end: Since the proteasome is responsible for the regulated turnover of I-kB, proteasome inhibitors might also alleviate psoriasis by blocking NF-kB activation. (2002-02-27)

Fox Chase Cancer Center offers topical gel to treat precursor to skin cancer
Researchers at Fox Chase Cancer Center are conducting an innovative clinical trial using bexarotene (Targretin®), a form of vitamin A in a topical gel, to treat parapsoriasis and prevent the disease from progressing into cancer. (2002-01-22)

ENBREL is first therapy approved for psoriatic arthritis
U.S. Food and Drug Administration (FDA) has approved ENBREL (etanercept) to treat people with psoriatic arthritis. ENBREL is the first therapy to receive approval to reduce the signs and symptoms of active arthritis in patients with psoriatic arthritis. (2002-01-16)

Molecular insight into wound healing
Scientists have discovered a critical protein involved in skin inflammation. Published in Genes & Development, this study sheds new light on the moleuclar mechanism of wound healing and identifies a potential new target in the treatment of skin disorders like psoriasis. (2001-12-14)

Phase 3 psoriatic arthritis data for ENBREL® (etanercept) announced at a national scientific meeting
Phase 3 results of ENBREL® (etanercept) studied in patients with psoriatic arthritis will be presented this week at the 65th Annual American College of Rheumatology National Scientific Meeting in San Francisco. These data are currently being reviewed by the FDA for potential approval of ENBREL for the treatment of psoriatic arthritis. (2001-11-12)

Increased risk of skin cancer for psoriasis patients given ciclosporin
The risk of squamous cell cancer of the skin is increased in patients treated for psoriasis with ciclosporin in addition to photochemotherapy, conclude authors of a study in this week's issue of THE LANCET. (2001-09-27)

The skin's acid coating: SFVAMC researchers explain its origin and how it maintains skin integrity
Acid on the skin might sound disturbing, but the mild acidity of the skin's surface actually helps to maintain the strength and cohesiveness of the skin. Now researchers at SFVAMC have discovered where this acidity comes from, and they suggest how it may help to hold the skin together. (2001-08-15)

Page 13 of 14 | 534 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.